ProCE Banner Activity

Interactive Tool for Managing BTK Inhibitor−Associated AEs in Hematologic Malignancies: A Global Perspective

Tool

Use this Interactive Decision Support Tool to learn strategies to assess and manage adverse events associated with BTK inhibitors from 5 international experts in managing patients with hematologic malignancies.

Released: August 15, 2023

Share

Faculty

Florence Cymbalista

Florence Cymbalista, MD, PhD

Professor of Hematology
Sorbonne Paris Nord University
Bobigny, France

Toby Eyre

Toby Eyre, MBChB, MD

Honorary Senior Lecturer
Hematology and Cancer
University of Oxford
Consultant Hematologist
Department of Hematology
Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom

Arnon Kater

Arnon Kater, MD, PhD

Professor
Hematologist
Deputy Head
Department of Hematology
Amsterdam University Medical Centers
University of Amsterdam
Amsterdam, Netherlands

Stephan Stilgenbauer

Stephan Stilgenbauer, MD

Medical Director Comprehensive Cancer Center Ulm
Head, Early Clinical Trials Unit
Head, Division of CLL Dept. of Internal Medicine III
University Medical Center
Ulm University
Ulm, Germany

Alessandra Tedeschi

Alessandra Tedeschi, MD

Director of Indolent Lymphoproliferative Disorders
Department of Hematology
Niguarda Cancer Center
Niguarda Hospital
Milan, Italy

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Faculty Disclosure

Primary Author

Florence Cymbalista, MD, PhD

Professor of Hematology
Sorbonne Paris Nord University
Bobigny, France

Florence Cymbalista, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, Janssen, Lilly.

Toby Eyre, MBChB, MD

Honorary Senior Lecturer
Hematology and Cancer
University of Oxford
Consultant Hematologist
Department of Hematology
Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom

Toby Eyre, MBCHB, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Autolus, Beigene, Incyte, Janssen, Kite/Gilead, Lilly, Roche, Secura Bio; researcher: AstraZeneca, Beigene.

Arnon Kater, MD, PhD

Professor
Hematologist
Deputy Head
Department of Hematology
Amsterdam University Medical Centers
University of Amsterdam
Amsterdam, Netherlands

Arnon Kater, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, Bristol-Myers Squibb, Janssen, Lava, LINK Immunotherapeutics, Roche/Genentech.

Stephan Stilgenbauer, MD

Medical Director Comprehensive Cancer Center Ulm
Head, Early Clinical Trials Unit
Head, Division of CLL Dept. of Internal Medicine III
University Medical Center
Ulm University
Ulm, Germany

Stephan Stilgenbauer, MD: consultant/advisor/speaker: AbbVie, Acerta, Amgen, AstraZeneca, BeiGene, Bristol-Myers Squibb, Celgene, Gilead, GlaxoSmithKline, Hoffmann-La Roche, Infinity, Janssen, Novartis, Sunesis, Verastem; research support: AbbVie, Acerta, Amgen, AstraZeneca, BeiGene, Bristol-Myers Squibb, Celgene, Gilead, GlaxoSmithKline, Hoffmann-La Roche, Infinity, Janssen, Novartis, Sunesis, Verastem. 

Alessandra Tedeschi, MD

Director of Indolent Lymphoproliferative Disorders
Department of Hematology
Niguarda Cancer Center
Niguarda Hospital
Milan, Italy

Alessandra Tedeschi, MD: Consultant/Advisor/Speaker: AbbVie, AstraZeneca, Beigene, Janssen.